These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 6929407)
21. Barnyard biotech--lame duck or golden goose? Powell K Nat Biotechnol; 2003 Sep; 21(9):965-7. PubMed ID: 12949546 [No Abstract] [Full Text] [Related]
22. Genomic sciences and the medicine of tomorrow. Drews J Nat Biotechnol; 1996 Nov; 14(11):1516-8. PubMed ID: 9634812 [No Abstract] [Full Text] [Related]
23. Company seeking donors of DNA for a 'gene trust'. Pollack A N Y Times Web; 2000 Aug; ():A1,C10. PubMed ID: 11873799 [No Abstract] [Full Text] [Related]
24. [Plant genetic engineering in Monsanto company: from the first laboratory experiments to worldwide practical use]. Konov AL; Velchev M; Parcel D Tsitol Genet; 2005; 39(3):3-12. PubMed ID: 16250241 [TBL] [Abstract][Full Text] [Related]
25. Foundation Review: Transgenic animals and their impact on the drug discovery industry. Dunn DA; Pinkert CA; Kooyman DL Drug Discov Today; 2005 Jun; 10(11):757-67. PubMed ID: 15922934 [TBL] [Abstract][Full Text] [Related]
26. Gene activation and EPO. Davidson S Nat Biotechnol; 1997 Jun; 15(6):497. PubMed ID: 9181561 [No Abstract] [Full Text] [Related]
27. BIO 2003--International Biotechnology Convention and Exhibition. Company pipelines. 21-25 June 2003, Washington, DC, USA. Waterworth C; Aird J IDrugs; 2003 Aug; 6(8):731-2. PubMed ID: 12971386 [No Abstract] [Full Text] [Related]
28. How do you measure "success" in a biotechnology company? Greetham EM Nat Biotechnol; 1998 May; 16 Suppl():59-60. PubMed ID: 9591275 [No Abstract] [Full Text] [Related]
30. [Production of autologous keratinocytes for therapeutic purposes within a pharmaceutical company]. Guillot FL J Soc Biol; 2001; 195(1):75-7. PubMed ID: 11530505 [TBL] [Abstract][Full Text] [Related]
31. BIO 2006 Annual International Convention. The expanding biotech industry of France. Zarkowska T IDrugs; 2006 Jun; 9(6):383-5. PubMed ID: 16752302 [No Abstract] [Full Text] [Related]
32. French drug developers face HIV fallout. Science; 1993 Mar; 259(5102):1698-9. PubMed ID: 8456296 [No Abstract] [Full Text] [Related]
33. Upping the ante on antibodies. Baker M Nat Biotechnol; 2005 Sep; 23(9):1065-72. PubMed ID: 16151393 [TBL] [Abstract][Full Text] [Related]
34. Swiss company takes a 60 per cent stake in Genentech. Gershon D Nature; 1990 Feb; 343(6258):495. PubMed ID: 2300193 [No Abstract] [Full Text] [Related]
36. The future of gene therapy in the UK. Seymour LW Trends Biotechnol; 2006 Aug; 24(8):347-9. PubMed ID: 16782218 [TBL] [Abstract][Full Text] [Related]
37. Rhône-Poulenc to focus biotech work on gene therapy. Butler D Nature; 1994 May; 369(6476):92. PubMed ID: 8177328 [No Abstract] [Full Text] [Related]
38. ReNeuron and StemCells get green light for neural stem cell trials. Mack GS Nat Biotechnol; 2011 Feb; 29(2):95-7. PubMed ID: 21301419 [No Abstract] [Full Text] [Related]
39. Exploitation of biotechnology in a smaller company. Fairtlough GH Philos Trans R Soc Lond B Biol Sci; 1989 Aug; 324(1224):589-97. PubMed ID: 2573092 [TBL] [Abstract][Full Text] [Related]
40. Genetic engineering. New european release rules ratified. Aldhous P Nature; 1990 Mar; 344(6265):371. PubMed ID: 2320103 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]